Is Monte Rosa Therapeutics Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: GLUE) stock is to Hold GLUE stock.
Out of 1 analyst, 0 (0%) are recommending GLUE as a Strong Buy, 0 (0%) are recommending GLUE as a Buy, 1 (100%) are recommending GLUE as a Hold, 0 (0%) are recommending GLUE as a Sell, and 0 (0%) are recommending GLUE as a Strong Sell.
What is GLUE's forecast return on equity (ROE) for 2023-2026?
(NASDAQ: GLUE) forecast ROE is N/A, which is considered weak.
What is GLUE's Price Target?
According to 1 Wall Street analyst that have issued a 1 year GLUE price target, the average GLUE price target is $11.00, with the highest GLUE stock price forecast at $11.00 and the lowest GLUE stock price forecast at $11.00.
The Wall Street analyst predicted that Monte Rosa Therapeutics's share price could reach $11.00 by Aug 11, 2024. The average Monte Rosa Therapeutics stock price prediction forecasts a potential upside of 72.14% from the current GLUE share price of $6.39.
What is GLUE's forecast return on assets (ROA) for 2023-2026?
(NASDAQ: GLUE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.1%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.